Dr Ali is currently PI on several trials investigating new treatments for SLE and RA. He is also developing a patient centric app to predict flares in RA that should improve care and outcome.
Embrace Study: phase 3/4, multi-center, randomized, double-blind, placebo-controlled,52-week study to evaluate the efficacy and safety of belimumab (HGS1006) in adult subjects of black race with SLE
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy
BM, Royal Free Hospital School of Medicine
MD, Royal Free Hospital School of Medicine. University of London
Residency, Internal Medicine, Oregon Health & Science University-OHSU GME